
Cambridge Healthtech Institute’s 8th Annual
Macrocyclics & Constrained Peptides
Discovery and Design of Cell-Penetrating, Middle-Sized Molecules for Oral-Based Medicines
April 14-15, 2020
In the drug discovery industry, synthetic macrocyclic compounds theoretically fit the bill for new chemical entities that have good drug potential yet can access newer drug targets such as protein-protein interactions (PPIs) that are intracellular and more complex than traditional enzymatic targets. Indeed, there are examples of naturally occurring macrocyclics, such as cyclosporin, that have become successful drug compounds. Synthetic macrocyclics' 'idealness' however is still being optimized. Please join us to stay abreast and discuss challenges that remain in the discovery, design and optimization of macrocyclic compounds or constrained peptides with good oral bioavailability and cell penetration.
Preliminary Agenda
NEW APPROACHES FOR CONSTRUCTING MACROCYCLIC SCAFFOLDS
Encoded Library Approaches for Macrocyclic Peptide-Based Drug Discovery
Christoph Dumelin, PhD, Investigator III, Chemical Biology & Therapeutics (CBT), Novartis Pharma AG
Macrocycles to Control Peptide Conformation and Activity
Paramjit Arora, PhD, Professor, Chemistry, New York University
New Chemistries for Macrocyclic Scaffolds
Laura Itzhaki, PhD, Professor, Pharmacology, University of Cambridge
Selection Methodology for Macrocyclics from DEL Campaigns
Chris Phelps, PhD, Manager, R&D Platform Technology & Science, GlaxoSmithKline Boston
CONSTRAINED PEPTIDES
Cyclotides as Scaffolds for Intracellular Targets
David Craik, PhD, ARC Laureate Fellow – Group Leader, Institute for Molecular Bioscience, Queensland University, Australia
Constrained Peptides for Drug Discovery
Rami Hannoush, PhD, Principal Scientist, Group Leader, Early Drug Biochemistry, Genentech
MACROCYCLIC-BASED DRUG LEADS
Type IV Macrocyclic Inhibitors of BRAF Kinase Block Paradoxical Signaling in Resistant Melanomas
Campbell McInnes, PhD, Professor, Drug Discovery and Biomedical Sciences, University of South Carolina
Cell-Based Production and Selection of PPI-Modulating Compounds
Maria Soloveychik, PhD, CEO, SnyntheX
Syrbactin Proteasome Inhibitors for Oncology and Immune Disorders
Michael Pirrung, PhD, Distinguished Professor of Chemistry, University of California Riverside
* The program is subject to change without notice, due to unforeseen reason.
Sponsor updated
Agenda,Sponsor updated